Company intelligence / Profile preview

SOM Biotech

Montcada i Reixac / Barcelona area*, Catalonia, Spainsombiotech.com ↗
Ownership
Private
Employees
~17
Development stage
Phase 2
01

Overview

Lead product SOM3355 has successfully completed Phase IIb trials in patients with Huntington's Disease chorea showing robust improvements in chorea symptoms without adverse effects such as somnolence, akathisia, depression or cognitive impact. The FDA granted Orphan Drug Designation for this compound. Other programs have reached Phase IIa proof-of-concept stages with positive outcomes[1][2][6][8].

Therapeutic areas
Metabolic DisordersOncologyRare DiseasesNeurologyInfectious Diseases
Modalities
Small molecules (e.g., β blocker SOM3355)Drug repurposing using AI technology
Industry
Biotech
02

Drug pipeline

5 assets

bevantolol

2

4 more assets in the full pipeline.

Request access →
03

Partnerships

Collaborations include Nippon Chemiphar (Japan) for the SOM3355 program[2], licensing agreements like Corino Therapeutics Inc. for TTR amyloidosis asset[2], plus multiple academic collaborations and industry partnerships[1][2].

Beyond the preview

Go deeper on SOM Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOM Biotech.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call